Document Detail


Clinical effects of recombinant human interleukin-3.
MedLine Citation:
PMID:  2048566     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Interleukin-3 (IL-3) is a glycoprotein belonging to the hematopoietic growth factor family that in preclinical in vitro and in vivo studies has exhibited a multilineage activity. Phase I/II trials with recombinant human IL-3 (rhIL-3) expressed in yeast are being done in patients with advanced malignancies as well as in patients with bone marrow failure states. Subcutaneous administration of rhIL-3 at dosages between 30 and 500 micrograms/m2 for 15 consecutive days has resulted in a dose-dependent increase in platelet counts as well as in a substantial increase in the number of circulating neutrophils, eosinophils, monocytes, and lymphocytes in patients with advanced malignancies but normal hematopoiesis. Erythropoiesis is less stimulated with an increase in hemoglobin concentration only in a minority of patients. In patients with secondary hematopoietic failure due to prolonged chemo-/radiotherapy or bone marrow infiltration by tumor cells, treatment with rhIL-3 leads to a clinically significant restoration of hematopoiesis, especially of thrombopoiesis and granulopoiesis. rhIL-3 has also been shown to improve neutrophil and platelet counts in patients with myelodysplastic syndromes, while improvement of hematopoiesis is rarely observed in patients with severe aplastic anemia with the presently used treatment schedules. Adverse effects of rhIL-3 are minor at the clinically used dosages and include fever, bone pain, headache, and stiffness of the neck. Transient thrombocytopenia has been observed in a few patients with myelodysplastic syndrome or aplastic anemia treated at dosages of 250-500 micrograms/m2. rhIL-3 is a multilineage hematopoietic cytokine with promising effects on platelet and neutrophil counts and special usefulness in patients with secondary hematopoietic failure.
Authors:
A Ganser; A Lindemann; G Seipelt; O G Ottmann; F Herrmann; M Eder; J Frisch; G Schulz; R Mertelsmann; D Hoelzer
Related Documents :
3470576 - Day 4 bone marrow aspirate for prediction of resistance to induction chemotherapy in ac...
21481156 - Ventricular arrhythmia in dialysis patients: a link with higher hemoglobin levels?
24620626 - Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome whi...
19513576 - Bone turnover in patients with endogenous cushing's syndrome before and after successfu...
7225966 - Resection for chronic alcoholic pancreatitis.
20641106 - Clinical features of the dilated phase of hypertrophic cardiomyopathy in comparison wit...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of clinical oncology     Volume:  14 Suppl 1     ISSN:  0277-3732     ISO Abbreviation:  Am. J. Clin. Oncol.     Publication Date:  1991  
Date Detail:
Created Date:  1991-07-17     Completed Date:  1991-07-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S51-63     Citation Subset:  IM    
Affiliation:
Department of Hematology, University of Frankfurt, F.R.G.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Aplastic / therapy
Animals
Blood Cell Count / drug effects
Clinical Trials as Topic
Dose-Response Relationship, Drug
Hematopoiesis / drug effects
Humans
Interleukin-3 / pharmacokinetics,  therapeutic use*
Myelodysplastic Syndromes / therapy
Neoplasms / therapy*
Recombinant Proteins / therapeutic use
Chemical
Reg. No./Substance:
0/Interleukin-3; 0/Recombinant Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Autologous bone marrow transplantation in hematological malignancies.
Next Document:  Coupling between the heart and arterial system in heart failure.